67 related articles for article (PubMed ID: 21291689)
1. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B.
Sniderman A; Tremblay A; Bergeron J; Gagné C; Couture P
J Clin Lipidol; 2007 Aug; 1(4):256-63. PubMed ID: 21291689
[TBL] [Abstract][Full Text] [Related]
2. The spectrum of type III hyperlipoproteinemia.
Sniderman AD; de Graaf J; Thanassoulis G; Tremblay AJ; Martin SS; Couture P
J Clin Lipidol; 2018; 12(6):1383-1389. PubMed ID: 30318453
[TBL] [Abstract][Full Text] [Related]
3. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in the development of radioimmunoassays for human serum lipoproteins.
Karlin JB; Juhn DJ; Goldberg R; Rubenstein AH
Ann Clin Lab Sci; 1978; 8(2):142-54. PubMed ID: 205163
[TBL] [Abstract][Full Text] [Related]
6. Typing of hyperlipoproteinemia in an Israel hospital.
Eisenberg S
Isr J Med Sci; 1976 Nov; 12(11):1261-8. PubMed ID: 1017927
[TBL] [Abstract][Full Text] [Related]
7. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme gene polymorphism, lipids, and apolipoproteins in menopausal women on hormone replacement therapy.
Cubrilo-Turek M; Sertić J; Duraković Z
Acta Med Croatica; 2001; 55(4-5):161-7. PubMed ID: 12398019
[TBL] [Abstract][Full Text] [Related]
9. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
Madej A; Okopien B; Kowalski J; Zielinski M; Wysocki J; Szygula B; Kalina Z; Herman ZS
Int J Clin Pharmacol Ther; 1998 Jun; 36(6):345-9. PubMed ID: 9660044
[TBL] [Abstract][Full Text] [Related]
10. Detection of dyslipoproteinemia with the use of plasma total cholesterol and triglyceride as screening tests. The Lipid Research Clinics Program Prevalence Study.
Kwiterovich PO; Stewart P; Probstfield JL; Stinnett S; Chambless LE; Chase GA; Jacobs DR; Morrison JA
Circulation; 1986 Jan; 73(1 Pt 2):I30-9. PubMed ID: 3940681
[TBL] [Abstract][Full Text] [Related]
11. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
[TBL] [Abstract][Full Text] [Related]
12. [Application of the immunoenzyme technic in double determination of antibodies for the study of hyperlipoproteinemia].
Kandoussi A; Cachera C; Reade R; Tacquet A; Fruchart JC
Ann Biol Clin (Paris); 1990; 48(6):365-8. PubMed ID: 2221495
[TBL] [Abstract][Full Text] [Related]
13. Plasma lipoprotein pattern and decreased platelet function in type V hyperlipoproteinemia.
Aviram M; Brook JG
Isr J Med Sci; 1985 Nov; 21(11):898-904. PubMed ID: 4077486
[TBL] [Abstract][Full Text] [Related]
14. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
Artery; 1985; 12(6):363-81. PubMed ID: 4051756
[TBL] [Abstract][Full Text] [Related]
15. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Takeda R
Artery; 1979 Feb; 5(2):125-43. PubMed ID: 231951
[TBL] [Abstract][Full Text] [Related]
16. Plasma lipoprotein levels and the prevalence of hyperlipoproteinemia in a Canadian working population.
Jones GJ; Hewitt D; Godin GJ; Breckenridge WC; Bird J; Mishkel MA; Steiner G; Little JA
Can Med Assoc J; 1980 Jan; 122(1):37-8, 40-6. PubMed ID: 7363194
[TBL] [Abstract][Full Text] [Related]
17. Apolipoproteins in diabetes dyslipidaemia in South Asians with young adult-onset diabetes: distribution, associations and patterns.
Katulanda GW; Katulanda P; Adler AI; Peiris SR; Draisey I; Wijeratne S; Sheriff R; Matthews DR; Shine B
Ann Clin Biochem; 2010 Jan; 47(Pt 1):29-34. PubMed ID: 19952033
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome.
Hu P; Lu L; Hu B; Du PF
Scand J Clin Lab Invest; 2009; 69(6):680-6. PubMed ID: 19468931
[TBL] [Abstract][Full Text] [Related]
19. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias.
de Graaf J; Couture P; Sniderman A
Nat Clin Pract Endocrinol Metab; 2008 Nov; 4(11):608-18. PubMed ID: 18838971
[TBL] [Abstract][Full Text] [Related]
20. Decrease of plasma large, light LDL (LDL1), HDL2 and HDL3 levels with concomitant increase of cholesteryl ester transfer protein (CETP) activity by probucol in type II hyperlipoproteinemia.
Homma Y; Kobayashi T; Yamaguchi H; Sakane H; Ozawa H; Matsuda M; Mikami Y; Mikami Y; Nakamura H
Artery; 1993; 20(1):1-18. PubMed ID: 8447724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
